A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
| Autor: | Judith Everts-Graber, Ueli Studer, Stephan Reichenbach, Hans Rudolf Ziswiler, Thomas Lehmann |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Endocrinology Diabetes and Metabolism Osteoporosis Urology 030209 endocrinology & metabolism Zoledronic Acid 03 medical and health sciences 0302 clinical medicine Bone Density medicine Humans Orthopedics and Sports Medicine 610 Medicine & health Osteoporosis Postmenopausal Bone mineral Postmenopausal women Bone Density Conservation Agents business.industry Significant difference medicine.disease Confidence interval Discontinuation Postmenopause 030104 developmental biology Denosumab Female business 360 Social problems & social services Bone mass medicine.drug |
| Zdroj: | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchReferences. 35(7) |
| ISSN: | 1523-4681 |
| Popis: | Discontinuation of denosumab is associated with a rapid return of bone mineral density (BMD) to baseline and an increased risk of multiple vertebral fractures. No subsequent treatment regimen has yet been established for preventing either loss of BMD or multiple vertebral fractures after denosumab discontinuation. The aim of this 8-year observational study was to investigate the effect of a single zoledronate infusion, administered 6 months after the last denosumab injection, on fracture occurrence and loss of BMD. We report on 120 women with postmenopausal osteoporosis who were treated with 60 mg denosumab every 6 months for 2 to 5 years (mean duration 3 years) and then 5 mg zoledronate 6 months after the last denosumab injection. All patients were evaluated clinically, by dual-energy X-ray absorptiometry (DXA) and vertebral fracture assessment (VFA), before the first and after the last denosumab injection and at 2.5 years (median) after denosumab discontinuation. During this off-treatment period, 3 vertebral fractures (1.1 per 100 patient-years) and 4 nonvertebral fractures (1.5 per 100 patient-years) occurred. No patients developed multiple vertebral fractures. Sixty-six percent (confidence interval [CI] 57% to 75%) of BMD gained with denosumab was retained at the lumbar spine and 49% (CI 31% to 67%) at the total hip. There was no significant difference in the decrease of BMD between patients with BMD gains of >9% versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text